Red Flags Detected
- Material Weakness (removed) — The 2024 filing disclosed a material weakness from 2023; the 2025 filing removes all material weakness discussion and reports effective controls.
- Securities Litigation (new) — New securities class action filed alleging material misrepresentations about OLC manufacturing and NDA approval prospects.
Unicycive resubmits OLC drug application after manufacturing setback, faces securities litigation
Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read
Key Changes
-
high
FDA issued Complete Response Letter in June 2025 due to third-party manufacturing vendor deficiencies; NDA resubmitted December 2025 with new approval target date of June 29, 2026—a one-year delay from original timeline.
Business: OLC regulatory status verify on EDGAR → -
high
Securities class action filed August 2025 alleging material misrepresentations about OLC manufacturing and approval prospects; two derivative suits and shareholder demand followed, all based on same alleged misconduct.
Legal Proceedings verify on EDGAR → -
high
Net loss decreased 28% to $26.6M as R&D expenses fell 54% while G&A expenses surged 69% to $20.4M, reflecting shift from clinical trials to commercial launch preparation.
MD&A: Operating expenses verify on EDGAR →
2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade UNCY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 6:44 PM